EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series

Marc Scherlinger, Yannick Dieudonné, Stéphane Hilliquin, Emmanuel Chatelus, Roberto d'Alessandro, Vincent Gies, Benoit Nespola, Thierry Martin, Jacques-Eric Gottenberg, Celestine Simand, Anne El Aatmani, Marie Laure Brandely-Piat und 5 weitere

Annals of the Rheumatic Diseases · 2026-06 · 85 (6) · 1172-1179

DOI: 10.1016/j.ard.2026.02.002 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-06. Verfasst von Marc Scherlinger und 16 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Centre de référence des maladies auto-immunes systémiques rares RESO, Hôpitaux Universitaires de Strasbourg, Strasbourg, Fra…. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Antibodies, Bispecific. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation Bettencourt Schueller, Foundation for Research in Rheumatology, Institut National de la Santé et de la Recherche Médicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aims to evaluate the safety, biological activity, and exploratory clinical effects of CD19-directed T-cell engagement with blinatumomab in patients with severe, treatment-refractory antitopoisomerase I-positive systemic sclerosis (SSc). METHODS: We conducted an exploratory case series of 5 patients with refractory SSc who received a 14-day continuous intravenous infusion of blinatumomab (9 µg/d for 7 days, escalated to 28 µg/d for 7 days) in 2 tertiary hospitals. Safety assessments included cytokine release syndrome (CRS), neurotoxicity, infections, and serum immunoglobulin levels. Exploratory efficacy outcomes comprised modified Rodnan skin score (mRSS), pulmonary function tests, and patient-reported outcomes. Immunologic endpoints included serial peripheral CD19⁺ B-cell counts, B-cell subset phenotyping, and a 6-gene type I interferon signature. Patients' follow-up was a median of 8 months (range: 6-12). RESULTS: Blinatumomab administration was generally well tolerated. Three patients experienced low-grade CRS (grade 1, n = 2; grade 2, n = 1), managed conservatively; no neurotoxicity or severe infections occurred. Rapid peripheral CD19⁺ B-cell depletion was achieved in all patients. B-cell repopulation occurred by 1 month in all but 1 patient and was dominated by naïve and transitional subsets. At 3 months, modest clinical improvements were observed, including a median mRSS change of -4 points (range: +1 to -8) from a baseline of 16 (range: 0-25) and a transient improvement in lung function and patient-reported outcomes. However, all patients experienced clinical relapse between months 3 and 6, leading to resumption of immunosuppressive therapy in most cases. CONCLUSIONS: CD19-directed T-cell engagement with blinatumomab induces rapid B-cell depletion and short-term clinical improvement in refractory SSc but lacks durability after a single treatment cycle.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicAntibodies, BispecificHumansFemaleMiddle AgedTreatment OutcomeMaleAntigens, CD19AdultInfusions, IntravenousAgedB-LymphocytesCytokine Release SyndromeT-Lymphocytes

Substanzen

Antibodies, BispecificblinatumomabAntigens, CD19

Autor:innen und Institutionen

  • Rheumatology Department, Centre de référence des maladies auto-immunes systémiques rares RESO, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; UMR INSERM 1109, Immunorhumatologie moléculaire, Strasbourg, Fran…
  • UMR INSERM 1109, Immunorhumatologie moléculaire, Strasbourg, France; Clinical Immunology Department, Centre de référence des maladies auto-immunes systémiques rares RESO, Hôpitaux Universitaires de Strasbourg, Strasbour…
  • Rheumatology Department, Assistance Publique Hôpitaux de Paris Hôpital Cochin, INSERM U1016, UMR8104, Paris, France.
  • Rheumatology Department, Centre de référence des maladies auto-immunes systémiques rares RESO, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • UMR INSERM 1109, Immunorhumatologie moléculaire, Strasbourg, France; Immunology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Immunology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Förderung

  • Fondation Bettencourt Schueller
  • Foundation for Research in Rheumatology
  • Institut National de la Santé et de la Recherche Médicale

Zitieren

APA

Scherlinger, M., Dieudonné, Y., Hilliquin, S., Chatelus, E., d'Alessandro, R., Gies, V., Nespola, B., Martin, T., Gottenberg, J. E., Simand, C., El Aatmani, A., Brandely-Piat, M. L., Sebbag, E., Decroocq, J., Sibilia, J., Allanore, Y., & Avouac, J. (2026). Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series. Annals of the Rheumatic Diseases, 85(6), 1172-1179. https://doi.org/10.1016/j.ard.2026.02.002

Vancouver

Scherlinger M, Dieudonné Y, Hilliquin S, Chatelus E, d'Alessandro R, Gies V, et al. Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series. Annals of the Rheumatic Diseases. 2026;85(6):1172-1179. doi:10.1016/j.ard.2026.02.002

BibTeX
@article{Scherlinger2026,
  author = {Scherlinger, Marc and Dieudonné, Yannick and Hilliquin, Stéphane and Chatelus, Emmanuel and d'Alessandro, Roberto and Gies, Vincent and Nespola, Benoit and Martin, Thierry and Gottenberg, Jacques-Eric and Simand, Celestine and El Aatmani, Anne and Brandely-Piat, Marie Laure and Sebbag, Eden and Decroocq, Justine and Sibilia, Jean and Allanore, Yannick and Avouac, Jerome},
  title = {Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  volume = {85},
  number = {6},
  pages = {1172--1179},
  doi = {10.1016/j.ard.2026.02.002}
}
Kostenlos starten →